{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:11:08Z","timestamp":1773112268617,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Botulinum toxin (BoNT) might improve spasticity-plus syndrome (SPS) in multiple sclerosis (MS) through peripheral inhibition of muscle contraction and central modulation of pain pathways, as hypothesized for migraine headaches. Hereby, we aim to explore changes in migraine headaches and SPS symptoms after BoNT treatment for MS-related spasticity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited 9 people with MS who received BoNT injection due to spasticity and with significant impact due to migraine headaches (mean age 48.6\u2009\u00b1\u20096.4 years; 55.5% females; median EDSS 6.0). At the time of BoNT injection and after 1 and 3 months, patients filled in the Migraine Disability Assessment Test (MIDAS), the short form Headache Impact Test (HIT-6), the Migraine Specific Quality of Life Questionnaire (MSQ), the Beck Depression Inventory-II (BDI-II), the Fatigue Severity Scale (FSS), and the Pittsburgh Sleep Quality Index (PSQI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      On linear mixed-effect models, we observed significant improvements in MIDAS (Coeff=-2.61; 95%CI=-4.39, -0.83;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), HIT-6 (Coeff=-1.89; 95%CI=-3.34, -4.45;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010), FSS (Coeff=-3.14; 95%CI=-5.62, -0.66;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013), and sleep efficiency (Coeff=-2.28; 95%CI=-4.17, -0.39;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018) and disturbance (Coeff=-0.18; 95%CI=-0.30, -0.06;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), which were proportional to BoNT dosing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BoNT may represent a promising treatment for the management of SPS symptoms, possibly thanks to its peripheral and central effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-025-08585-x","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:03:26Z","timestamp":1767485006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A proof-of-concept study on the effectiveness of botulinum toxin on spasticity plus syndrome in multiple sclerosis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-3090","authenticated-orcid":false,"given":"Marcello","family":"Moccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Braca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"8585_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.802918","volume":"12","author":"A Bruno","year":"2022","unstructured":"Bruno A, Dolcetti E, Centonze D (2022) Theoretical and therapeutic implications of the Spasticity-Plus syndrome model in multiple sclerosis. Front Neurol 12:1\u20137. https:\/\/doi.org\/10.3389\/fneur.2021.802918","journal-title":"Front Neurol"},{"key":"8585_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.722801","volume":"12","author":"O Fernandez","year":"2021","unstructured":"Fernandez O, Costa-Frossard L, Mart\u00ednez-Gin\u00e9s ML et al (2021) Integrated management of multiple sclerosis spasticity and associated symptoms using the spasticity-Plus syndrome concept: results of a structured specialists\u2019 discussion using the Workmat\u00ae methodology. Front Neurol 12:1\u201311. https:\/\/doi.org\/10.3389\/fneur.2021.722801","journal-title":"Front Neurol"},{"key":"8585_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/011570159x329058240820070701","volume":"23","author":"A Bruno","year":"2024","unstructured":"Bruno A, Annovazzi P, Clerico M et al (2024) Disease-Modifying symptomatic treatment (DMST) potential of cannabinoids in patients with multiple sclerosis. Curr Neuropharmacol 23:503\u2013510. https:\/\/doi.org\/10.2174\/011570159x329058240820070701","journal-title":"Curr Neuropharmacol"},{"key":"8585_CR4","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/ene.15412","volume":"29","author":"F Patti","year":"2022","unstructured":"Patti F, Chisari CG, Fern\u00e1ndez \u00d3 et al (2022) A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: analysis in relation to the newly described \u2018spasticity-plus syndrome\u2019. Eur J Neurol 29:2744\u20132753. https:\/\/doi.org\/10.1111\/ene.15412","journal-title":"Eur J Neurol"},{"key":"8585_CR5","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s10072-020-04392-8","volume":"41","author":"M Moccia","year":"2020","unstructured":"Moccia M, Frau J, Carotenuto A et al (2020) Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. Neurol Sci 41:2781\u20132792. https:\/\/doi.org\/10.1007\/s10072-020-04392-8","journal-title":"Neurol Sci"},{"key":"8585_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/14737175.2013.865880","volume":"13","author":"R Gold","year":"2013","unstructured":"Gold R, Oreja-Guevara C (2013) Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother 13:55\u201359. https:\/\/doi.org\/10.1586\/14737175.2013.865880","journal-title":"Expert Rev Neurother"},{"key":"8585_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/toxins15050332","volume":"15","author":"MT Corasaniti","year":"2023","unstructured":"Corasaniti MT, Bagetta G, Nicotera P et al (2023) Safety of onabotulinumtoxin A in chronic migraine: A systematic review and Meta-Analysis of randomized clinical trials. Toxins (Basel) 15:1\u201320. https:\/\/doi.org\/10.3390\/toxins15050332","journal-title":"Toxins (Basel)"},{"key":"8585_CR8","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1111\/bph.12763","volume":"171","author":"R Ramachandran","year":"2014","unstructured":"Ramachandran R, Yaksh TL (2014) Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol 171:4177\u20134192. https:\/\/doi.org\/10.1111\/bph.12763","journal-title":"Br J Pharmacol"},{"key":"8585_CR9","doi-asserted-by":"publisher","first-page":"E32600","DOI":"10.1097\/MD.0000000000032600","volume":"102","author":"CC Turkel","year":"2023","unstructured":"Turkel CC, Aurora S, Diener HC et al (2023) Treatment of chronic migraine with botox (onabotulinumtoxinA): Development, insights, and impact. Med (United States) 102:E32600. https:\/\/doi.org\/10.1097\/MD.0000000000032600","journal-title":"Med (United States)"},{"key":"8585_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/toxins16120530","volume":"16","author":"MP Prudenzano","year":"2024","unstructured":"Prudenzano MP (2024) Botulinum toxin and migraine: goals and perspectives. Toxins (Basel) 16:530. https:\/\/doi.org\/10.3390\/toxins16120530","journal-title":"Toxins (Basel)"},{"key":"8585_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jclinepi.2004.05.004","volume":"57","author":"M Martin","year":"2004","unstructured":"Martin M, Blaisdell B, Kwong JW, Bjorner JB (2004) The Short-Form headache impact test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol 57:1271\u20131278. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.05.004","journal-title":"J Clin Epidemiol"},{"key":"8585_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/toxins14110774","volume":"14","author":"F Novarella","year":"2022","unstructured":"Novarella F, Carotenuto A, Cipullo P et al (2022) Persistence with botulinum toxin treatment for spasticity symptoms in multiple sclerosis. Toxins (Basel) 14:1\u20138. https:\/\/doi.org\/10.3390\/toxins14110774","journal-title":"Toxins (Basel)"},{"key":"8585_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/ene.14110","volume":"27","author":"G Comi","year":"2019","unstructured":"Comi G, Solari A, Leocani L et al (2019) Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol 27:445\u2013453. https:\/\/doi.org\/10.1111\/ene.14110","journal-title":"Eur J Neurol"},{"key":"8585_CR14","unstructured":"World Health Organization (2020) ICF Browser. http:\/\/apps.who.int\/classifications\/icfbrowser\/"},{"key":"8585_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1046\/J.0333-1024.2001.00277.X","volume":"21","author":"D D\u2019Amico","year":"2001","unstructured":"D\u2019Amico D, Mosconi P, Genco S et al (2001) The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 21:947\u2013952. https:\/\/doi.org\/10.1046\/J.0333-1024.2001.00277.X","journal-title":"Cephalalgia"},{"key":"8585_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/S11136-013-0556-9","volume":"23","author":"A Raggi","year":"2014","unstructured":"Raggi A, Giovannetti AM, Schiavolin S et al (2014) Validating the Migraine-Specific quality of life questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse. Qual Life Res 23:1273\u20131277. https:\/\/doi.org\/10.1007\/S11136-013-0556-9","journal-title":"Qual Life Res"},{"key":"8585_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0160261","volume":"11","author":"C Solaro","year":"2016","unstructured":"Solaro C, Trabucco E, Signori A et al (2016) Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: an Italian multi-center study using the Beck depression inventory. PLoS ONE 11:1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0160261","journal-title":"PLoS ONE"},{"key":"8585_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2340\/16501977-2116","volume":"48","author":"M Ottonello","year":"2016","unstructured":"Ottonello M, Pellicciari L, Giordano A, Foti C (2016) Rasch analysis of the fatigue severity scale in Italian subjects with multiple sclerosis. J Rehabil Med 48:597\u2013603. https:\/\/doi.org\/10.2340\/16501977-2116","journal-title":"J Rehabil Med"},{"key":"8585_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10072-012-1085-y","volume":"34","author":"G Curcio","year":"2013","unstructured":"Curcio G, Tempesta D, Scarlata S et al (2013) Validity of the Italian version of the Pittsburgh sleep quality index (PSQI). Neurol Sci 34:511\u2013519. https:\/\/doi.org\/10.1007\/s10072-012-1085-y","journal-title":"Neurol Sci"},{"key":"8585_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00702-013-1145-3","volume":"121","author":"A Schramm","year":"2014","unstructured":"Schramm A, Ndayisaba J, auf dem Brinke M et al (2014) Spasticity treatment with onabotulinumtoxin A : data from a prospective German real-life patient registry. J Neural Transm 121:521\u2013530. https:\/\/doi.org\/10.1007\/s00702-013-1145-3","journal-title":"J Neural Transm"},{"key":"8585_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2024.1360032","volume":"15","author":"H Goicochea Brice\u00f1o","year":"2024","unstructured":"Goicochea Brice\u00f1o H, Higueras Y, Ruiz P\u00e9rez I et al (2024) Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain. Front Neurol 15:1\u20138. https:\/\/doi.org\/10.3389\/fneur.2024.1360032","journal-title":"Front Neurol"},{"key":"8585_CR22","doi-asserted-by":"publisher","unstructured":"Raciti L, Raciti G, Militi D et al (2022) Chronic migraine: A narrative review on the use of botulinum toxin with clinical indications and future directions. J Integr Neurosci 21. https:\/\/doi.org\/10.31083\/j.jin2105141","DOI":"10.31083\/j.jin2105141"},{"key":"8585_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2024.1371644","volume":"15","author":"\u00d3 Fern\u00e1ndez Fern\u00e1ndez","year":"2024","unstructured":"Fern\u00e1ndez Fern\u00e1ndez \u00d3, Costa-Frossard L, Mart\u00ednez Gin\u00e9s ML et al (2024) Practical tool to identify Spasticity-Plus syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis. Front Neurol 15:1\u201310. https:\/\/doi.org\/10.3389\/fneur.2024.1371644","journal-title":"Front Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08585-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:05:00Z","timestamp":1773068700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["8585"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08585-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the committee of Federico II University of Naples, Italy (355\/19). All of the patients signed informed consent prior to the study and data processing authorization (GDPR 2016\/679). The study was conducted in accordance with good clinical practice and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Authors declare no potential conflict of interest in relation to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"90"}}